



تأثيرات المعملات مساعد الإنزيم كيو ١٠ و فيتامين (هـ) على التشنجات التي يسببها البنتيلين تترازول و التدهور الإدراكي الناجم عن الفينيتوين في الجرذان

رسالة مقدمة من الصيدلانية

هروة محمد نجيب فهمي

ماجستير علوم صيدليه، جامعة عين شمس (٢٠١٣)
مدرس مساعد علم الأدوية والسموم، كلية الصيدلة، جامعة مصر الدولية
رسالة مقدمة لاستكمال متطلبات الحصول على درجة الدكتوراة في العلوم الصيدلية
(علم الأدوية والسموم)

تحت إشراف

أ.د/ سميرة ابراهيم مسعود

أ.د/ نجوي علي صبري

أستاذ ورئيس قسم الصيدلة الإكلينيكية
أستاذ متفرغ ورئيس قسم علم الأدوية
كلية الصيدلة، جامعة عين شمس
الإكلينيكي، كلية الطب، جامعة عين شمس

د/ ماريان جورج تادرس

أستاذ مساعد علم الأدوية والسموم
كلية الصيدلة، جامعة عين شمس

د/ رانيا محمد رحمو

مدرس علم الأدوية والسموم
كلية الصيدلة، جامعة مصر الدولية
كلية الصيدلة - جامعة عين شمس

(٢٠١٨)



Effects of Coenzyme Q 10 and Vitamin E supplementation on Pentylentetrazole-induced seizures and Phenytoin-induced cognitive impairment in rats

Thesis presented by

Marwa Mohamed Nagib Fahmy

M.Sc., Ain Shams University (2013)

Assistant Lecturer of Pharmacology and Toxicology,
Faculty of Pharmacy, Misr International University

Submitted for fulfillment of PhD degree in Pharmaceutical Sciences, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University

Under the supervision

Dr. Nagwa Ali Sabri

Professor and Head of Clinical Pharmacy
Department, Faculty of Pharmacy,
Ain Shams University

Dr. Somaia Ibrahim Masoud

Professor and Former Head of Clinical
Pharmacology Department, Faculty of
Medicine, Ain Shams University

Dr. Mariane George Tadros

Assistant Professor of Pharmacology and Toxicology
Faculty of Pharmacy, Ain Shams University

Dr. Rania Mohamed Rahmo

Lecturer of Pharmacology and Toxicology
Faculty of Pharmacy, Misr International University
Faculty of Pharmacy-Ain Shams University
(2018)

قَالَ اللَّهُ تَعَالَى :

وَقُلْ رَبِّ زِدْنِي ^{عِلْمًا}

(طه: 114)



Examination Board Approval Sheet

Name of Candidate

Marwa Mohamed Nagib Fahmy Abdel Ghani

Title of Thesis

**Effects of Coenzyme Q 10 and Vitamin E supplementation on
Pentylenetetrazole-induced seizures and Phenytoin-induced
cognitive impairment in rats**

Submitted to Faculty of Pharmacy, Ain Shams University
Department of Pharmacology and Toxicology

Approved by the committee in charge:

- **Dr. Somaia Ibrahim Masoud**

Professor and Former Head of Clinical Pharmacology Department, Faculty of Medicine, Ain Shams University.

- **Dr. Nemat El-Baz Mohamed**

Professor and Former Head of Pharmacology Department, Faculty of Medicine for Girls, Al-Azhar University.

- **Dr. Nagwa Ali Sabri**

Professor and Head of Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University.

- **Dr. Hala Mahmoud Fawzy**

Professor and Head of the General Division of Pharmacology Department, National Organization for Drug Control and Research (NODCAR).

- **Dr. Mariane George Tadros**

Assistant Professor of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University.

Pre-requisite Postgraduate Courses

Besides the work presented in the thesis, the candidate has attended pre-requisite postgraduate courses including the following topics:

Special Courses:

- Clinical Pharmacology
- Pharmacology
- Selected Topics
- Clinical Toxicology

The candidate has successfully passed the examination in these courses and the comprehensive exam with general grade "***Excellent***".

Head of Pharmacology and Toxicology Department
Faculty of Pharmacy, Ain Shams University
Prof. Ebtahal El-Demerdash Zaki

ACKNOWLEDGMENTS

*Primarily, I am thankful to Almighty **Allah** for His showers of blessings and granting me the capability to believe in myself and pursue my dreams. Without Him, this achievement would not have been possible. My doctoral work appears in its present form as a result of the support of several people. I would so like to offer my sincere thanks to all of them.*

*I am extremely indebted to my principal supervisor, **Dr. Nagwa Ali Sabri** Professor and Head of Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University for her patience through the entire duration of the study, enthusiasm, motivation and immense knowledge. Without her supervision, this thesis would not have been possible.*

*I would also like to express my sincere gratitude to my supervisor, **Dr. Somaia Ibrahim Masoud**, Professor and Former Head of Clinical Pharmacology Department, Faculty of Medicine, Ain Shams University for the continuous support of my Ph.D study and related research. Her constructive comments helped me in all the time of research and writing of this thesis.*

*Special appreciation and gratitude go to my supervisor **Dr. Mariane George Tadros**, Assistant Professor of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University for her motivation and support during the whole period of the research. Her valuable instructions have served as the major contributor towards the completion of this thesis.*

*I would also like to acknowledge my supervisor **Dr. Rania Mohamed Rahmo**, Lecturer of Pharmacology and Toxicology, Faculty of Pharmacy, Misr International University for her faithful guidance, kind supervision and understanding. I was fortunate to work alongside with her, wishing that our companionship will last forever.*

*I would like to extend my deepest appreciation to **Dr. Amani Emam Khalifa**, Professor of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, seconded to 57357 Children Cancer Hospital as the Scientific Consultant for Pharmacy Affairs for suggesting the point of the thesis and I owe her the utmost degree of gratefulness. It was a great honor to complete this work under her observation.*

*I wish to sincerely thank **Dr. Hadwa Ali Abdel-khalek**, Lecturer of Histology and Cell Biology, Faculty of Medicine, Ain Shams University for her kind cooperation in the histopathological and immunohistochemical parts and the critical comments throughout the study.*

*I am also very thankful to the Technical Assistant, **Rabiey Taha** who helped me with every obstacle regarding my practical work.*

*It is my great pleasure to thank **all members of Pharmacology and Toxicology Department, Faculty of Pharmacy, Ain Shams University and my colleagues in Misr International University** who reinforced me and aided me in my way.*

*My deepest thankfulness is also to **my family**, especially **my mother** for her financial support and continuous prayers to finish this work. She has taught me persistence and high morals. Without her encouragement and genuine care, I could not have finished this thesis.*

*A special thanks to my husband and love of my life, **Dr. Mohamed Abdelsalam**, who has been a constant source of support and encouragement during the challenges of my thesis. I am truly thankful for having you in my life.*

*I would like to take the opportunity to gratefully acknowledge my mentor, **late Dr. Moushira Ibrahim El Sayed**, Professor of Pharmacology and Toxicology and Head of the department Faculty of Pharmacy, Sinai University for her motivation and encouragement. Her profound knowledge and kindness inspired me to pursue my doctoral research in the field of pharmacology. I wish her soul rest in peace.*

*Last but not the least, this thesis is dedicated to **my late father** who has been my main source of inspiration. I am most grateful to him, he never stopped giving me all the encouragement I needed to accomplish my dreams. His priceless advices were always pushing me forward. Papa, this is for you, may your soul rest in peace.*

Marwa Mohamed Nagib

Table of contents

SUBJECT	PAGE
<i>List of Abbreviations</i>	i
<i>List of Tables</i>	iv
<i>List of Figures</i>	vii
<i>List of Photomicrographs</i>	xi
<i>Abstract</i>	xii




LITERATURE REVIEW

1. Overview	1
2. Classification of epileptic seizures	2
2.1. Partial seizures	2
2.2. Generalized seizures	3
3. Diagnosis	3
4. Seizure triggers	5
4.1. Food additives	5
4.2. Electrolytes imbalance	6
4.3. Environmental toxins and stress	6
5. Pathophysiology of epilepsy	7
5.1. Nuclear factor-erythroid 2-related factor 2 (Nrf2) signaling pathway	8
5.2. Silencing information regulator 1 (SIRT1) pathway	11
5.3. Role of glial cells in epilepsy	14
6. Experimental models	17
6.1. Aluminum hydroxide model	17
6.2. Audiogenic model	17
6.3. Photo-sensitive baboon model	18
6.4. Bicuculine model	19
6.5. Cobalt model	20



6.6. Electric shock seizure model	21
6.7. Gamma-aminobutyric acid (GABA) abstinence	21
6.8. Kainic acid model (KA)	22
6.9. Kindling model	22
6.10. Pentylenetetrazole (PTZ) model	24
6.11. Penicillin model	25
6.12. Pilocarpine model	26
6.13. Zinc model	27
7. <i>Therapy for epilepsy</i>	28
7.1. Antiepileptic drugs (AEDs)	28
7.2. Surgical intervention	31
7.3. Vagal nerve stimulation (VNS)	32
7.4. Deep brain stimulation (DBS)	33
7.5. Transcranial magnetic stimulation (TMS)	33
7.6. The ketogenic diet	34
7.7. Hormones	35
7.8. Natural and complementary therapies	36
7.8.1. Vitamins and minerals	36
7.8.2. Melatonin	37
7.8.3. Polyunsaturated Fatty Acids (PUFAs)	37
7.8.4. Resveratrol	38
7.8.5. Phytocannabinoids (PCBs)	39
8. <i>The drugs used in the current study</i>	40
8.1. DL-alpha-Tocopherol (α -Toc)	40
8.1.1. Chemical properties	40
8.1.2. Pharmacodynamic and pharmacokinetic properties	41
8.2. Coenzyme Q10 (CoQ10)	44
8.2.1. Chemical properties	44
8.2.2. Pharmacodynamic and pharmacokinetic properties	45
8.3. Phenytoin (PHT)	48
8.3.1. Chemical properties	48
8.3.2. Pharmacodynamic and pharmacokinetic properties	49
AIM OF THE WORK	53

MATERIALS AND METHODS

A. Experimental Design	56
B. Materials	59
1. Animals	59
2. Drugs	59
2.1. DL-alpha-Tocopherol (α -Toc)	59
2.2. Coenzyme Q10 (CoQ10)	59
2.3. Pentylenetetrazole (PTZ)	59
2.4. Phenytoin (PHT)	60
3. Antibodies	60
3.1. Ionized calcium binding adaptor molecule 1 (Iba1)	60
3.2. Glial fibrillary acidic protein (GFAP)	60
4. Chemicals and solutions	60
4.1. Bovine Serum Albumin (BSA)	60
4.2. Formalin	60
4.3. Sodium chloride	60
4.4. Potassium dihydrogen phosphate	60
4.5. Sodium dibasic phosphate	60
4.6. Urethane	60
5. Buffers	61
5.1. Phosphate buffer saline (PBS)	61
6. Enzyme-linked immunosorbent assay (ELISA) kits	61
6.1. RayBio® Rat TNF-alpha ELISA Kit (RayBiotech Co., USA)	61
6.2. Rat NF- κ B ELISA kit (EIAab, Hubei, P. R. China)	62
6.3. DNA-Binding ELISA Kit (LSBio™, Seattle, WA, USA)	63
6.4. Nuclear factor-erythroid 2-related factor 2 (Nrf2) ELISA kit (Cloud-Clone Corp., USA)	64
6.5. Protein assay kit (Bio-rad Laboratories, Inc., California, USA)	64
7. Reverse transcription polymerase chain reaction (RT-PCR) kits	65
7.1. RNeasy Mini Kit (Qiagen N.V., Hilden, Germany)	65
7.2. High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, California, USA)	65
7.3. SYBR® Green PCR Master Mix (Applied Biosystems, California, USA)	65

8. Apparatuses	66
8.1. Cooling centrifuge	66
8.2. Basic Homogenizer	66
8.3. Microplate reader	66
8.4. Sensitive balance	66
8.5. Real time RT-PCR system	66
8.6. Image analyzer	66
C. Methods	67
 Section I	67
1. Behavioral tests	67
1.1. Average Racine score	67
2. Tissue preparation, histopathological examination, immunohistochemical staining and morphometric studies	68
2.1. Tissue preparation	68
2.2. Histopathological examination	68
2.3. Immunohistochemical staining	68
2.4. Morphometric studies	69
3. Biochemical tests	70
3.1. Cortical and hippocampal processing	70
3.2. Determination of protein content (Bradford protein assay kit)	70
3.3. Determination of tumor necrosis factor alpha (TNF- α) concentration in rat hippocampal and cortical tissues	72
3.4. Determination of nuclear factor kappa B (NF- κ B) concentration in rat hippocampal and cortical tissues	76
3.5. Determination of nuclear factor-erythroid 2-related factor 2 (Nrf2) concentration in rat hippocampal and cortical tissues	79
3.6. Determination of HO-1, NQO1, SIRT 1 and PGC1- α gene expression	86
 Section II	94
1. Behavioral tests	94
1.1. Novel object recognition (NOR) test	94
1.2. Elevated plus maze (EPM) test	96
2. Biochemical tests	97
2.1. Determination of VEGF, BDNF, TrkB and CREB gene expression	97
 Statistical analysis	98

RESULTS

 Section I	99
1. Behavioral tests	99
1.1. Effect on PTZ-induced seizure activity	99
2. Histopathological examination, immunohistochemical studies	101
2.1. Histopathological examination	101
2.1.1. Effect on percentage of dark neurons	101
2.2. Immunohistochemical studies	109
2.2.1. Effect on GFAP area percentage	109
2.2.2. Effect on Iba1 area percentage	115
3. Biochemical tests	121
3.1. Inflammatory markers	121
3.1.1. Tumor necrosis factor alpha (TNF- α) concentrations in cortex (CX) and hippocampus (HP) of rats	121
3.1.2. Nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B) concentrations in cortex (CX) and hippocampus (HP) of rats	125
3.2. Nuclear factor-erythroid 2-related factor 2 (Nrf2) signaling pathway	129
3.2.1. The nuclear levels of Nrf2 in cortex (CX) and hippocampus (HP) of rats	129
3.2.2. Effect on cortical and hippocampal heme oxygenase-1 (HO-1) gene expression	133
3.2.3. Effect on cortical and hippocampal NAD(P)H: quinone oxidoreductase-1 (NQO1) gene expression	137
3.3. Silencing information regulator 1 (SIRT1) signaling pathway	141
3.3.1. Effect on cortical and hippocampal SIRT1 gene expression	141
3.3.2. Effect on cortical and hippocampal peroxisome proliferator-activated receptor-gamma co-activator 1 alpha (PGC-1 α) gene expression	145
 Section II	149
1. Behavioral tests	149
1.1. Effect on novel object recognition (NOR) test	149
1.2. Effect on elevated plus maze (EPM) test	151

2. <i>Biochemical tests</i>	153
2.1. Effect on vascular endothelial growth factor (VEGF) gene expression in prefrontal cortex (PFCX) and hippocampus (HP)	153
2.2. Effect on brain derived neurotrophic factor (BDNF) gene expression in prefrontal cortex (PFCX) and hippocampus (HP)	156
2.3. Effect on tyrosine receptor kinase B (TrKB) gene expression in prefrontal cortex (PFCX) and hippocampus (HP)	159
2.4. Effect on cyclic AMP (cAMP)-responsive element-binding protein (CREB) gene expression in prefrontal cortex (PFCX) and hippocampus (HP)	162

DISCUSSION	165
SUMMARY AND CONCLUSIONS	185
REFERENCES	199
ARABIC SUMMARY	

List of Abbreviations

AEDs	Anti-epileptic drugs
AD	Alzheimer's disease
AREs	Antioxidant response elements
α-Toc	DL-alpha-Tocopherol
AM	Amygdala
AMPA	Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
ANOVA	Analysis of variance
ATP	Adenosine triphosphate
BDNF	Brain derived neurotrophic factor
BW	Body weight
BSA	Bovine serum albumin
CA1	Region I of hippocampus proper
CA3	Region III of hippocampus proper
CAMK	Calmodulin-dependent protein kinase
CBZ	Carbamazepine
cDNA	Complementary deoxyribonucleic acid
CoQ10	Coenzyme Q10
CREB	Cyclic AMP (cAMP)-responsive element-binding protein
CX	Cortex
CNS	Central nervous system
CT	Cycle threshold
DBS	Deep brain stimulation
DG	Dentate gyrus
DI	Discrimination index
EEG	Electroencephalogram
ELISA	Enzyme-linked immunosorbent assay
ETC	Electron transport chain
EPM	Elevated plus maze
GAD	Glutamate decarboxylase
GAPDH	Glyceraldehyde 3-phosphate dehydrogenase
GFAP	Glial fibrillary acidic protein
GSH	Reduced glutathione
GABA	Gamma-aminobutyric acid
H&E	Hematoxylin & eosin
HP	Hippocampus
HO-1	Heme oxygenase-1
HRP	Horseradish peroxidase

List of Abbreviations

Iba1	Ionized calcium binding adaptor molecule 1
IgG	Immunoglobulin G
IL-1β	Interleukin-1-beta
KA	Kainic acid
MDA	Malondialdehyde
mRNA	Messenger ribonucleic acid
MSG	Monosodium glutamate
NAD	Nicotinamide adenine dinucleotide
NF-κB	Nuclear Factor kappa-light chain enhancer of activated B cells
NMDA	N-methyl-D-aspartate
NOR	Novel object recognition
NQO1	NAD(P)H:quinone oxidoreductase 1
Nrf2	Nuclear factor-erythroid 2-related factor 2
OD	Optical density
PBS	Phosphate buffer saline
PHT	Phenytoin
PCBs	Phytocannabinoids
PGC-1α	Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha
PκB α	Phosphorylated inhibitory kappa B- α
PUFAs	Polyunsaturated fatty acids
PO	Per os
PPI	Protease and phosphatase inhibitors
PFCX	Prefrontal cortex
PTZ	Pentylentetrazole
RNA	Ribonucleic acid
ROS	Reactive oxygen species
RT-PCR	Reverse transcription polymerase chain reaction
SE	Status epilepticus
SN	Substantia nigra
Sir2	Silent information regulator 2
SIRT6	Sirtuins
SOD	Superoxide dismutase
TL	Transfer latency
TLE	Temporal lobe epilepsy
TMB	Tetra methyl benzidine
Tmax	Time at which peak serum concentration is reached
TMS	Transcranial Magnetic Stimulation
TNF-α	Tumor necrosis factor-alpha